EBRO 2017

Surgery vs. neoadjuvant chemotherapy + surgery

EBRO 2017

• Rationale: control early spread of systemic disease • MAGIC study (Cunningham) may not be generalisable to all esophageal adenocarcinoma (26% EGJ/adeno) • Meta-analyses favor neoadjuvant chemotherapy over surgery alone

Pennathur et al, Lancet 2013